Gemini Therapeutics, a Cambridge, MA-based new precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases, completed a $42.5m Series A financing.
The round was co-led by Atlas Venture, Lightstone Ventures and OrbiMed.
The company intends to use the funds to advance multiple programs into the clinic.
Led by James McLaughlin, CEO, president and co-founder, and Scott Lauder Ph.D., senior vice president of process development and manufacturing, Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Its therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies.
The company’s discovery and development efforts are powered by partnerships and technology from research institutions including the University of Edinburgh, Newcastle University (UK), and the Sanquin Blood Supply Foundation in the Netherlands, as well as innovative companies including StrideBio, Inc.
The scientific founders of Gemini include the University of Edinburgh’s Paul Barlow, Ph.D., and Andy Herbert, Ph.D., and Tufts University’s Johanna Seddon, M.D., M.Sc.